CDK

Cat. No.

A54449

CAS No.

3027994-03-9

CDK4-IN-4

CDK4-IN-4 is a selective inhibitor of Cyclin-dependent kinase 4 (CDK4), with an IC50 value of less than 10 nM. This compound plays a critical role in cancer research by selectively interfering with cell cycle regulation, thus inhibiting the proliferation of cancer cells. CDK4-IN-4 is suitable for studies focusing on cell cycle dynamics and the therapeutic potential of CDK4 inhibition in various cancer models.

Cat. No.

A54450

CAS No.

1817006-50-0

CDK7-IN-5

CDK7-IN-5 is a selective inhibitor of cyclin-dependent kinase 7 (CDK7) with an IC50 value of less than 100 nM. This compound exhibits significant anticancer activity, making it a valuable tool in cancer research. Its ability to modulate transcriptional regulation positions CDK7-IN-5 as a promising candidate for studies aimed at investigating novel therapeutic strategies for cancer treatment.

Cat. No.

A54452

CAS No.

237392-85-7

Cdk2/Cyclin Inhibitory Peptide II

Cdk2/Cyclin Inhibitory Peptide II is a specific inhibitor of cyclin-dependent kinase 2 (CDK2), primarily influencing cell cycle regulation. This peptide has demonstrated the ability to induce apoptosis in U2OS osteosarcoma cells in a dose-dependent manner. Its application in research includes investigations into cell cycle dynamics and therapeutic strategies for cancer treatment.

Cat. No.

A54453

CAS No.

933009-51-9

CDK1-IN-7

CDK1-IN-7 is a potent inhibitor of Cyclin-dependent kinase 1 (CDK1). It effectively inhibits the proliferation and migration of colorectal cancer cell lines, including HCT116 and Lovo. This compound serves as a valuable tool for investigating the role of CDK1 in colorectal cancer research and therapeutic strategies.

Cat. No.

A54454

CAS No.

3038638-82-0

CDK2-IN-52

CDK2-IN-52 is a selective inhibitor of cyclin-dependent kinase 2 (CDK2), exhibiting an impressive DC50 value of 1-10 nM. This compound effectively induces cell cycle arrest and inhibits the proliferation of tumor cells, making it a valuable tool for studying CDK2-overexpressing malignancies such as breast and ovarian cancers. CDK2-IN-52 facilitates research into potential therapeutic strategies targeting CDK2 in cancer treatment.

Cat. No.

A54455

CAS No.

2862836-22-2

CDK2-IN-14

CDK2-IN-14 is a selective inhibitor of cyclin-dependent kinase 2 (CDK2), known for its potency in inhibiting cell cycle progression. This compound plays a significant role in cancer research, allowing for the exploration of CDK2's involvement in tumorigenesis and potential therapeutic interventions. CDK2-IN-14 is suitable for studies aimed at understanding the mechanisms of cell proliferation and offers potential insights into novel cancer treatment strategies.

Cat. No.

A54457

CAS No.

2380320-68-1

CDK4-IN-2

CDK4-IN-2 is a potent inhibitor of cyclin-dependent kinase 4 (CDK4) with a Ki and IC50 value of less than 10 nM. This compound effectively regulates cell cycle progression and is valuable in cancer research, particularly in studies focused on oncogenic signaling pathways and cell proliferation. It serves as a crucial tool for evaluating potential therapeutic strategies targeting CDK4 in various malignancies.

Cat. No.

A54458

CAS No.

3024545-83-0

CDK7-IN-29

CDK7-IN-29 is a potent inhibitor of cyclin-dependent kinase 7 (CDK7) with an IC50 value of 1.4 nM. This compound demonstrates oral bioavailability and favorable pharmacokinetic properties, making it suitable for in vivo studies. Its ability to inhibit CDK7 positions it as a valuable tool for investigating cellular processes related to transcription and cell cycle regulation, particularly in cancer research applications.

Cat. No.

A54459

CAS No.

2850253-95-9

CDK8-IN-9

CDK8-IN-9 is a potent type II cyclin-dependent kinase 8 (CDK8) inhibitor, exhibiting an IC50 value of 48.6 nM. This compound effectively inhibits tumor growth and serves as a valuable tool in colorectal cancer research. Its targeting of CDK8 makes it suitable for investigations into the molecular mechanisms underlying cancer progression and treatment responses.

Cat. No.

A54460

CAS No.

3051587-93-7

CDK2-IN-44

CDK2-IN-44 is a potent inhibitor of cyclin-dependent kinase 2 (CDK2), a crucial regulator of the cell cycle. This compound effectively blocks the proliferation of cancer cells by inducing cell cycle arrest, promoting apoptosis, and triggering cellular senescence. CDK2-IN-44 is particularly relevant for research applications focused on ovarian and breast cancer, offering valuable insights into therapeutic strategies targeting CDK2 activity.

Cat. No.

A54461

CAS No.

2649407-21-4

Cdc7-IN-9

Cdc7-IN-9 is a selective inhibitor of the Cdc7 kinase, a key regulator of DNA replication and cell cycle progression. This compound demonstrates significant biological activity in inhibiting cancer cell proliferation by disrupting the replication process. Cdc7-IN-9 is valuable for research applications focused on understanding the role of Cdc7 in cancer biology and developing targeted therapies for tumor treatment.

Cat. No.

A54463

CAS No.

3039540-24-1

CDK9 ligand 3

CDK9 ligand 3 is a selective inhibitor of cyclin-dependent kinase 9 (CDK9), known for its role in regulating transcriptional elongation. It serves as a crucial component in the synthesis of PROTAC CDK9 degrader-11, facilitating targeted protein degradation. This compound is valuable for research applications focused on cancer therapeutics and the modulation of gene expression through CDK9 inhibition.

Cat. No.

A54464

CAS No.

1908454-70-5

CDK4/6-IN-13

CDK4/6-IN-13 is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), pivotal regulators of the cell cycle. This compound demonstrates low nanomolar potency, exhibiting significant antiproliferative activity against various cancer cell lines. CDK4/6-IN-13 also offers favorable metabolic properties and pharmacokinetic profiles, making it a valuable tool for research in oncology and cell cycle regulation.

Cat. No.

A54465

CAS No.

2146171-49-3

Fovinaciclibum

Synonyms: Fovinaciclib

Fovinaciclibum is a cyclin-dependent kinase (CDK) inhibitor that demonstrates significant antineoplastic activity. This compound is designed to selectively inhibit CDK enzymes, thereby disrupting cell cycle progression and promoting apoptosis in cancer cells. It is utilized in research focusing on tumor biology and therapeutic strategies for various malignancies.

Cat. No.

A54466

CAS No.

1310059-06-3

Anticancer agent 300

Anticancer Agent 300 (compound P14) is a modulator of CCND1, CDK4, CDK6, and CCNE1, exhibiting significant anti-proliferative properties. This compound influences cell cycle regulation, induces senescence, and promotes apoptosis in cancer cells. It is applicable in research related to ER+/HER2− breast cancer and BRAF-mutant melanoma, providing valuable insights for cancer therapeutics.

Cat. No.

A54467

CAS No.

3032997-16-0

CDK1-IN-4

CDK1-IN-4 is a selective inhibitor of cyclin-dependent kinase 1 (CDK1), exhibiting IC50 values of 44.52 nM for CDK1, 624.93 nM for CDK2, and 135.22 nM for CDK5. This compound effectively disrupts the cell cycle, leading to inhibition of cancer cell proliferation. CDK1-IN-4 is suitable for research applications related to cancer biology and therapeutics targeting cell cycle regulation.

Cat. No.

A54468

CAS No.

2927473-94-5

CDK2-IN-27

CDK2-IN-27 is a selective inhibitor of cyclin-dependent kinase 2 (CDK2), demonstrating potent inhibition with IC50 values of less than 10 nM for the CDK2/cyclin E1 complex and 10-20 nM for the CDK2/cyclin B1 complex. This compound is crucial for studies focused on cell cycle regulation and cancer research, where CDK2 plays a significant role in cell proliferation. CDK2-IN-27 provides valuable insights into therapeutic strategies targeting CDK2 to halt tumor growth and enhance cancer treatment regimens.

Cat. No.

A54469

CAS No.

2411021-95-7

(R)-PROTAC CDK9 ligand-1

(R)-PROTAC CDK9 ligand-1 is a potent degrader targeting cyclin-dependent kinase 9 (CDK9), a key regulator of transcription and cell cycle progression. This compound facilitates the synthesis of PROTACs (proteolysis-targeting chimeras), which exhibit antitumor activity by promoting the degradation of CDK9. Research applications include investigations into cancer biology and therapeutic strategies aimed at modulating CDK9 levels for improved treatment outcomes.

Cat. No.

A54470

CAS No.

1056016-06-8

(R)-DRF053

(R)-DRF053 is a selective cyclin-dependent kinase (CDK) inhibitor that primarily targets Cdk5. This compound is known to enhance the formation of ductal precursor β cells, making it valuable for investigating pancreatic development and diabetes research. Additionally, (R)-DRF053 has been shown to inhibit Dil-ox-LDL uptake and reduce CD36 gene expression induced by advanced glycation end products (AGEs) in U937 cells, indicating its relevance in studies related to atherosclerosis and metabolic diseases.

Cat. No.

A54472

CAS No.

660822-23-1

CCT68127

Synonyms: αSβR-21

CCT68127 is a selective inhibitor of cyclin-dependent kinases (CDKs) that functions by disrupting cell cycle progression. This compound demonstrates significant anti-proliferative activity in various cancer cell lines, making it a valuable tool for cancer research. CCT68127 can be utilized to investigate CDK-related pathways and explore potential therapeutic strategies for malignancies.

Cat. No.

A54473

CAS No.

500735-47-7

Olomoucine II

Olomoucine II is a potent inhibitor of cyclin-dependent kinases (CDKs), specifically exhibiting IC50 values of 0.06 µM for CDK9/cyclin T, 0.1 µM for CDK2/cyclin E, 0.45 µM for CDK7/cyclin H, 7.6 µM for CDK1/cyclin B, and 19.8 µM for CDK4/cyclin D1. This compound demonstrates significant antiproliferative activity, making it a valuable tool for studies investigating cell cycle regulation and cancer biology. Its selectivity and efficacy position Olomoucine II as an important reagent for research applications aimed at understanding CDK-related pathways.

Cat. No.

A54474

CAS No.

1203565-13-2

CDK modulator 1

CDK Modulator 1 functions as a selective inhibitor of cyclin-dependent kinases (CDKs), influencing cell cycle progression. This compound has shown significant biological activity in blocking CDK activity, making it a valuable tool for research in cancer biology and cell proliferation studies. It is particularly useful in investigations related to cancer therapeutics and the regulation of cellular growth control pathways.

Cat. No.

A54476

CAS No.

677701-62-1

CDK1/2/4-IN-2

CDK1/2/4-IN-2 is a selective inhibitor of cyclin-dependent kinases 1, 2, and 4. This compound demonstrates significant anti-proliferative effects, making it a valuable tool for investigating cell cycle regulation and cancer biology. It is suitable for use in preclinical studies aimed at exploring therapeutic strategies for various malignancies.

Cat. No.

A54478

CAS No.

730945-59-2

CDK2-IN-39

CDK2-IN-39 is a selective inhibitor of cyclin-dependent kinase 2 (CDK2), a crucial regulator of the cell cycle. This compound demonstrates significant activity in modulating CDK2-mediated phosphorylation, making it a valuable tool for studies on cell proliferation, cancer research, and cellular signaling pathways. CDK2-IN-39 can help elucidate the role of CDK2 in the progression of various cancers and may aid in the development of therapeutic strategies targeting cell cycle dysregulation.

Cat. No.

A54479

CAS No.

2991229-06-0

CDK2-IN-21

CDK2-IN-21 is a selective inhibitor of cyclin-dependent kinase 2 (CDK2) with an IC50 of 0.24 µM. This compound demonstrates potent inhibitory activity, making it a valuable tool for cancer research. By targeting CDK2, CDK2-IN-21 can help elucidate the role of cell cycle regulation in tumorigenesis and facilitate the development of potential therapeutic strategies against cancer.